Using Amino Acid PET/MRI to Diagnose Brain Tumors
Diagnostic Assessment of Amino Acid PET/MRI in the Evaluation of Glioma and Brain Metastases
This study is testing if using a special imaging technique that combines amino acid PET and MRI can help doctors better diagnose brain tumors in adults who need surgery or a biopsy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 160 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Norwegian University of Science and Technology Academic / other |
| Drugs / interventions | radiation |
| Locations | 3 sites (Bergen and 2 other locations) |
| Trial ID | NCT04111588 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of combining amino acid PET with MRI for diagnosing gliomas and brain metastases. It aims to improve the accuracy of tumor grading, assess true tumor volume, and differentiate viable tumor tissue from treatment-induced changes. The study will involve adult patients who are scheduled for tissue sampling or surgery for brain tumors, utilizing promising amino acid PET tracers to enhance diagnostic capabilities. The research seeks to compare different PET tracers and their diagnostic value in various brain neoplasms.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years with planned treatment for gliomas or brain metastases requiring surgery or stereotactic radiosurgery.
Not a fit: Patients with incompatible medical devices, inability to provide informed consent, or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate diagnoses and better treatment planning for patients with brain tumors.
How similar studies have performed: Other studies have shown promising results with similar PET/MRI approaches, indicating potential for improved diagnostic accuracy.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Inclusion criteria Glioma (LGG, HGG and recurrent HGG): * Planned treatment for WHO grade II-IV diffuse glioma * Adult patients (\>18 years) * Planned tissue sampling for histopathological diagnosis. * KPS \>60 (able to care for self) Inclusion criteria Brain Metastasis: * Indication of surgery or stereotactic radiosurgery for 1-4 brain metastases * Planned surgery: Suspicion of brain metastasis or known diagnosis * Stereotactic surgery: Known primary cancer * Adult patients (\>18 years) * Estimated survival at least 3 months after inclusion Exclusion Criteria: * Exclusion criteria (Glioma and Brain Metastasis): * Pacemakers or defibrillators not compatible with 3T MRI * No ability to obtain informed consent (e.g. due to severe dysphasia or cognitive deficits). * Pregnancy (pregnancy test for all women in fertile age when doubt about possible pregnancy exist) * Breastfeeding * Weight \> 120 kg
Where this trial is running
Bergen and 2 other locations
- Haukeland universitetssykehus — Bergen, Norway (Not_yet_recruiting)
- Universitetssykehus Nord Norge — Tromsø, Norway (Not_yet_recruiting)
- St Olavs Hospital — Trondheim, Norway (Recruiting)
Study contacts
- Principal investigator: Live Eikenes, Phd — Norwegian University of Science and Technology
- Study coordinator: Live Eikenes, PhD
- Email: live.eikenes@ntnu.no
- Phone: 0047 99568081
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.